Back Ground: Bronchiectasis is a commonly seen chronic lung disease in our inpatient and outpatient services of QCH. The unmet needs of people with bonchiectasis are hug, with realitvely few randomised controlled trials (RCT's) and evidence-based interventions. This randomised-controlled-trial (RCT) aims to imporve the outcomes of these children. It will examine the benefits (or otherwise) of a novel medication, erosteine. Erosteine's effects include (a) mucolytic action modulation of mucus production and increasing muco-cilary transport; with (b) antioxidant; (c) airway anit inflmaatory and; (d) bacterial anit-adhesion properties. This RCT will answer: In children with bronchiectasis, does 12 months treatment with erosteine, compared to the placebo, (i) reduce acute respiratory exacerbations and/or (II) improve quality of life (QoL). The RCT will also determine the cost-effectiveness of the treatment. The findings of this RCT may alter routine clinical proactive if eroosteine is shown to improve the lives of children with bronchiectasis.